Microbot Medical Achieves Milestone Success with LIBERTY System

Groundbreaking Clinical Trial Results for LIBERTY System

Microbot Medical Inc. has recently unveiled impressive findings regarding its LIBERTY Endovascular Robotic System. Achieving a remarkable 100% success rate in robotic navigation, the results from this clinical trial highlight the innovative technology and its potential to change the landscape of endovascular procedures.

Study Overview

The pivotal ACCESS-PVI study was shared by Microbot Medical at a notable medical conference, where key data pointed to the efficacy and safety of the LIBERTY system in robotic endovascular surgeries. Carrying out tests at three premier medical facilities, the results underscored the system's potential to transform patient outcomes significantly.

Key Findings from the ACCESS-PVI Study

Robotic navigation was successfully executed in every instance, with the study involving 20 cases. This achievement exceeded expectations and met the primary objective of the trial. Highlighting the effectiveness of the LIBERTY system, here are some key figures from the study:

• Every case reached successful robotic navigation, achieving a perfect score of 100% success.
• No adverse device events were recorded throughout the follow-up, demonstrating the system's reliability.
• Notably, the average reduction in radiation exposure was an impressive 92%, emphasizing the system's safety.
• The average navigation time to target was a swift 3 minutes, showcasing efficiency in procedures.
• Participating doctors expressed high satisfaction levels, with a flawless performance rating reported.

Statements from Company Leadership

Harel Gadot, Chairman, CEO, and President of Microbot Medical, shared his enthusiasm for the trial results. "The ACCESS-PVI data reflects our team's dedication to the LIBERTY system. We are eager to transition into a commercial phase and are confident in a positive reception market-wide,” he said. This sentiment was echoed by Dr. Juan Diaz-Cartelle, the Chief Medical Officer, who emphasized the ease of use and quick learning curve associated with the system.

What Makes LIBERTY Unique?

The LIBERTY system is pioneering world-first single-use, fully disposable robotic technology, aiming to break down barriers previously encountered in accessing advanced robotic systems. Its innovative approach is designed to enhance medical service delivery and improve healthcare outcomes for patients globally. Upon receiving FDA clearance, the LIBERTY system is set to make significant waves within the medical community.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is on the verge of launching an innovative device that could drastically improve the endovascular process. As a pre-commercial stage company, they focus on addressing challenges faced by healthcare providers and patients alike, committed to facilitating advancements in medical technology.

Frequently Asked Questions

What is the significance of the LIBERTY Endovascular Robotic System?

The LIBERTY system represents a significant advancement in endovascular procedures, showcasing a 100% success rate in robotic navigation during trials.

Who presented the ACCESS-PVI study results?

The results were presented by Dr. Francois Cornelis during the Society of Interventional Radiology annual meeting, highlighting the study's critical findings.

How does the LIBERTY system reduce radiation exposure?

The advanced design and technology of the LIBERTY system have led to a significant reduction in radiation exposure for both patients and operators.

What feedback has the LIBERTY system received from physicians?

Physicians reported a 100% satisfaction rate with the LIBERTY system, noting its intuitive operation and effectiveness during procedures.

When is the LIBERTY system expected to launch?

The LIBERTY system is currently seeking FDA clearance, after which it is anticipated to be available in the market.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.